The new year will bring more data than the last 500 decades, information that will be used to improve clinical trial design and shorten drug development timelines, say industry experts.
While several companies touted the potential of AI to disrupt the drug development industry in 2018, what practical applications can the industry expect next year?
The new “groundbreaking” model can translate the results of mouse experiments into the equivalent human condition, outperforming traditional methods of extrapolation by up to 50%, say researchers.
PPD is adding nearly 6,000 square feet of new lab space – and about 20 employees – dedicated to gene and cell therapy analytical testing at its site in Athlone, Ireland.
A lobby group has filed a complaint alleging illegal discrimination by airlines refusing to transport lab animals – a battle that will be difficult to win, says an industry expert.
SPARC and Schrödinger will collaborate to use Schrödinger’s technological platforms and SPARC’s insights into research therapeutics for neurodegenerative conditions.
ABL named a successor to its previous CEO, Syneos has two new hires, and BTS Research appointed a VP to push its growth model. These, among other people on the move this month.
Evotec and Immuneering are combining iPSC and AI technologies through a research collaboration to discover novel small molecules for rare hereditary metabolic diseases.
Cyclica, a Bayer G4A company, will work with Bayer to advance drug discovery. The collaboration will involve looking further into polypharmacological profiles of small molecules.
Quanterix is expanding its biomarker technology platform to oncology with the launch of a new test bed for up to 10-plex assays, which will enable drug developers to expedite clinical trials, says CEO.
